Searchable abstracts of presentations at key conferences in endocrinology

ea0028s6.4 | Inhibiting steroid enzymes to treat common diseases | SFEBES2012

Potential prostate cancer drug therapy targets bioactivation of androstanediol to dihydrotestosterone

Mohler James , Titus Mark , Wilson Elizabeth

Prostate cancer development and progression depend on androgen signaling through the androgen receptor (AR). Recent evidence indicates the continued presence of intratumoral dihydrotestosterone (DHT) during androgen deprivation therapy drives prostate cancer recurrence through the activation of AR. There are ongoing efforts to identify drugs that target AR and enzymes that catalyze the synthesis of testosterone and DHT. Temporary remediation of prostate cancer by surgical or m...